Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsDGX +0.61%81 EV-to-FCF is 22.41 as of Jul. 18, 2026, which is 9% above its 10-year median of 20.63. GuruFocus rates DGX with a GF Score™ of 81/100 and a GF Value™ of $188.15 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Quest Diagnostics ranks better than 53.54% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quest Diagnostics's Enterprise Value is $29,714 Mil.
Quest Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1,326 Mil. Therefore, Quest Diagnostics's EV-to-FCF for today is 22.41.
The historical rank and industry rank for Quest Diagnostics's EV-to-FCF or its related term are showing as below:
DGX'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.74 Med: 20.63 Max: 34.57
Current: 22.41
During the past 13 years, the highest EV-to-FCF of Quest Diagnostics was 34.57. The lowest was 9.74. And the median was 20.63.
DGX's EV-to-FCF is ranked better than 53.54% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.75
vs DGX: 22.41
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quest Diagnostics's PE Ratio (TTM) for today is calculated as:
Quest Diagnostics's share price for today is $210.68.
Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Quest Diagnostics EV-to-FCF Related Terms
Quest Diagnostics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Quest Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's EV-to-FCF falls into.
Quest Diagnostics's current Enterprise Value is $29,714 Mil.
Quest Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,326 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (DGX) has a EV-to-FCF of 22.41 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quest Diagnostics and its competitors. This is near median its historical median of 20.63. Over the past decade, Quest Diagnostics' EV-to-FCF has ranged from 9.74 to 34.57. According to the industry distribution chart, Quest Diagnostics ranks #46 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 46.5%.
Is Quest Diagnostics' EV-to-FCF too high?
Quest Diagnostics' current EV-to-FCF of 22.41 is near median its 10-year median of 20.63. Over the past 10 years, this metric has ranged from a low of 9.74 to a high of 34.57. The Medical Diagnostics & Research industry median EV-to-FCF is 27.75. Quest Diagnostics' value of 22.41 is 19.2% below this industry median. Based on the distribution chart, Quest Diagnostics ranks #46 out of 99 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' EV-to-FCF compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #46 out of 99 companies for EV-to-FCF. This puts Quest Diagnostics in the upper half of its industry. The industry median EV-to-FCF is 27.75. Quest Diagnostics' value of 22.41 is 19.2% below this benchmark. Historically, Quest Diagnostics' own EV-to-FCF has ranged from 9.74 to 34.57 over the past decade. While the company's 10-year median is 20.63 vs. the industry median of 27.75, Quest Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.75, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current EV-to-FCF of 22.41 is 19.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current EV-to-FCF is 22.41, which is near median its own 10-year median of 20.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (DGX) is currently considered Modestly Overvalued. The stock's GF Value™ is $188.15, compared to a current price of $210.68 — trading 12% above its estimated fair value. The current EV-to-FCF is 22.41, which is near median its 10-year median of 20.63 and 19.2% below the Medical Diagnostics & Research industry median of 27.75. Quest Diagnostics' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Quest Diagnostics (DGX), the current EV-to-FCF is 22.41 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (DGX) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of $210.68 is trading 12% above its estimated GF Value™ of $188.15.
GuruFocus considers Quest Diagnostics to be Modestly Overvalued.
Key valuation signals for DGX:
EV-to-FCF: 22.41 (near median its 10-year median of 20.63)
GF Value™: $188.15 vs. price of $210.68 (12% above fair value)
Industry Position: 19.2% below the Medical Diagnostics & Research median (#46 of 99)
No single metric tells the full story. See the DGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
81GF Score
Get the complete analysis for DGX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGX has been successfully added to your 
